Posted inManufacturing News
Eli Lilly–Nimbus Deal, Alnylam Expansion Signal Strategic Shift in Biopharma Investment.
In early January 2026 the biopharmaceutical sector has seen a flurry of activity from billion-dollar licensing deals to significant infrastructure investments. These moves highlight a shared industry focus on obesity treatments, oncology…
